nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—L-Phenylalanine—Melphalan—ovarian cancer	0.744	1	CrCrCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—LMX1A—ovarian cancer	0.00448	0.182	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—LMX1A—ovarian cancer	0.00267	0.108	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—KLK6—ovarian cancer	0.0026	0.106	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—NSF—ovarian cancer	0.00135	0.0546	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—RBL2—ovarian cancer	0.00103	0.0417	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—PVRL2—ovarian cancer	0.000933	0.0379	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—RBL2—ovarian cancer	0.00091	0.0369	CbGpPWpGaD
Lisdexamfetamine—Body temperature increased—Chlorambucil—ovarian cancer	0.000847	0.00365	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000845	0.00365	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Paclitaxel—ovarian cancer	0.000844	0.00364	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Topotecan—ovarian cancer	0.00084	0.00362	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Melphalan—ovarian cancer	0.000833	0.00359	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Topotecan—ovarian cancer	0.000829	0.00358	CcSEcCtD
Lisdexamfetamine—SLC6A3—Monoamine Transport—PVRL2—ovarian cancer	0.000827	0.0335	CbGpPWpGaD
Lisdexamfetamine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000824	0.00355	CcSEcCtD
Lisdexamfetamine—Fatigue—Topotecan—ovarian cancer	0.000822	0.00355	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Melphalan—ovarian cancer	0.000822	0.00355	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000816	0.00352	CcSEcCtD
Lisdexamfetamine—Constipation—Topotecan—ovarian cancer	0.000816	0.00352	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000814	0.00351	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Melphalan—ovarian cancer	0.000812	0.0035	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000806	0.00348	CcSEcCtD
Lisdexamfetamine—Fatigue—Melphalan—ovarian cancer	0.000805	0.00347	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Vinorelbine—ovarian cancer	0.0008	0.00345	CcSEcCtD
Lisdexamfetamine—Tachycardia—Vinorelbine—ovarian cancer	0.000796	0.00343	CcSEcCtD
Lisdexamfetamine—Skin disorder—Vinorelbine—ovarian cancer	0.000793	0.00342	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000789	0.0034	CcSEcCtD
Lisdexamfetamine—Anorexia—Vinorelbine—ovarian cancer	0.000778	0.00335	CcSEcCtD
Lisdexamfetamine—Asthenia—Chlorambucil—ovarian cancer	0.000769	0.00332	CcSEcCtD
Lisdexamfetamine—Urticaria—Topotecan—ovarian cancer	0.000758	0.00327	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Topotecan—ovarian cancer	0.000754	0.00325	CcSEcCtD
Lisdexamfetamine—Weight increased—Docetaxel—ovarian cancer	0.000745	0.00321	CcSEcCtD
Lisdexamfetamine—Visual impairment—Paclitaxel—ovarian cancer	0.000745	0.00321	CcSEcCtD
Lisdexamfetamine—Urticaria—Melphalan—ovarian cancer	0.000742	0.0032	CcSEcCtD
Lisdexamfetamine—Weight decreased—Docetaxel—ovarian cancer	0.00074	0.00319	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Chlorambucil—ovarian cancer	0.000733	0.00316	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Paclitaxel—ovarian cancer	0.00073	0.00315	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Vinorelbine—ovarian cancer	0.000728	0.00314	CcSEcCtD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—PARK2—ovarian cancer	0.000724	0.0294	CbGpPWpGaD
Lisdexamfetamine—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.000723	0.00312	CcSEcCtD
Lisdexamfetamine—Eye disorder—Paclitaxel—ovarian cancer	0.000722	0.00311	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000719	0.0031	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Paclitaxel—ovarian cancer	0.000717	0.00309	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Docetaxel—ovarian cancer	0.000715	0.00308	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Vinorelbine—ovarian cancer	0.000709	0.00306	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000705	0.00304	CcSEcCtD
Lisdexamfetamine—Fatigue—Vinorelbine—ovarian cancer	0.000704	0.00303	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Topotecan—ovarian cancer	0.000703	0.00303	CcSEcCtD
Lisdexamfetamine—Constipation—Vinorelbine—ovarian cancer	0.000698	0.00301	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Paclitaxel—ovarian cancer	0.000698	0.00301	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000696	0.003	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00069	0.00298	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Melphalan—ovarian cancer	0.000688	0.00297	CcSEcCtD
Lisdexamfetamine—Asthenia—Topotecan—ovarian cancer	0.000684	0.00295	CcSEcCtD
Lisdexamfetamine—Vomiting—Chlorambucil—ovarian cancer	0.000681	0.00294	CcSEcCtD
Lisdexamfetamine—Mental disorder—Paclitaxel—ovarian cancer	0.000677	0.00292	CcSEcCtD
Lisdexamfetamine—Malnutrition—Paclitaxel—ovarian cancer	0.000673	0.0029	CcSEcCtD
Lisdexamfetamine—Asthenia—Melphalan—ovarian cancer	0.00067	0.00289	CcSEcCtD
Lisdexamfetamine—Hepatitis—Docetaxel—ovarian cancer	0.000655	0.00282	CcSEcCtD
Lisdexamfetamine—Nervousness—Paclitaxel—ovarian cancer	0.000653	0.00282	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Topotecan—ovarian cancer	0.000653	0.00281	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000652	0.00281	CcSEcCtD
Lisdexamfetamine—Urticaria—Vinorelbine—ovarian cancer	0.000648	0.0028	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Vinorelbine—ovarian cancer	0.000645	0.00278	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Melphalan—ovarian cancer	0.000639	0.00276	CcSEcCtD
Lisdexamfetamine—Diplopia—Epirubicin—ovarian cancer	0.000638	0.00275	CcSEcCtD
Lisdexamfetamine—Nausea—Chlorambucil—ovarian cancer	0.000636	0.00274	CcSEcCtD
Lisdexamfetamine—Vision blurred—Paclitaxel—ovarian cancer	0.000634	0.00273	CcSEcCtD
Lisdexamfetamine—Visual impairment—Docetaxel—ovarian cancer	0.000631	0.00272	CcSEcCtD
Lisdexamfetamine—Dizziness—Topotecan—ovarian cancer	0.000631	0.00272	CcSEcCtD
Lisdexamfetamine—Tremor—Paclitaxel—ovarian cancer	0.00063	0.00272	CcSEcCtD
Lisdexamfetamine—Affect lability—Epirubicin—ovarian cancer	0.000628	0.00271	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Docetaxel—ovarian cancer	0.000619	0.00267	CcSEcCtD
Lisdexamfetamine—Agitation—Paclitaxel—ovarian cancer	0.000618	0.00267	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—PARK2—ovarian cancer	0.000615	0.025	CbGpPWpGaD
Lisdexamfetamine—Angioedema—Paclitaxel—ovarian cancer	0.000615	0.00265	CcSEcCtD
Lisdexamfetamine—Eye disorder—Docetaxel—ovarian cancer	0.000612	0.00264	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Docetaxel—ovarian cancer	0.000608	0.00262	CcSEcCtD
Lisdexamfetamine—Vomiting—Topotecan—ovarian cancer	0.000607	0.00262	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000603	0.0026	CcSEcCtD
Lisdexamfetamine—Rash—Topotecan—ovarian cancer	0.000601	0.00259	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000601	0.00259	CcSEcCtD
Lisdexamfetamine—Dermatitis—Topotecan—ovarian cancer	0.000601	0.00259	CcSEcCtD
Lisdexamfetamine—Headache—Topotecan—ovarian cancer	0.000598	0.00258	CcSEcCtD
Lisdexamfetamine—Palpitations—Paclitaxel—ovarian cancer	0.000594	0.00256	CcSEcCtD
Lisdexamfetamine—Vomiting—Melphalan—ovarian cancer	0.000594	0.00256	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Docetaxel—ovarian cancer	0.000591	0.00255	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—ovarian cancer	0.000591	0.00255	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00059	0.00254	CcSEcCtD
Lisdexamfetamine—Rash—Melphalan—ovarian cancer	0.000589	0.00254	CcSEcCtD
Lisdexamfetamine—Dermatitis—Melphalan—ovarian cancer	0.000588	0.00254	CcSEcCtD
Lisdexamfetamine—Asthenia—Vinorelbine—ovarian cancer	0.000585	0.00252	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Epirubicin—ovarian cancer	0.000583	0.00251	CcSEcCtD
Lisdexamfetamine—Convulsion—Paclitaxel—ovarian cancer	0.000583	0.00251	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—ovarian cancer	0.000581	0.00251	CcSEcCtD
Lisdexamfetamine—Hypertension—Paclitaxel—ovarian cancer	0.000581	0.0025	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000575	0.00248	CcSEcCtD
Lisdexamfetamine—Mental disorder—Docetaxel—ovarian cancer	0.000574	0.00247	CcSEcCtD
Lisdexamfetamine—Anxiety—Paclitaxel—ovarian cancer	0.000571	0.00246	CcSEcCtD
Lisdexamfetamine—Malnutrition—Docetaxel—ovarian cancer	0.00057	0.00246	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000569	0.00245	CcSEcCtD
Lisdexamfetamine—Nausea—Topotecan—ovarian cancer	0.000567	0.00244	CcSEcCtD
Lisdexamfetamine—Dry mouth—Paclitaxel—ovarian cancer	0.00056	0.00241	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vinorelbine—ovarian cancer	0.000558	0.00241	CcSEcCtD
Lisdexamfetamine—Nausea—Melphalan—ovarian cancer	0.000555	0.00239	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000549	0.00237	CcSEcCtD
Lisdexamfetamine—Dizziness—Vinorelbine—ovarian cancer	0.00054	0.00233	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—ovarian cancer	0.00054	0.00233	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000538	0.00232	CcSEcCtD
Lisdexamfetamine—Tachycardia—Paclitaxel—ovarian cancer	0.000536	0.00231	CcSEcCtD
Lisdexamfetamine—Skin disorder—Paclitaxel—ovarian cancer	0.000533	0.0023	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000532	0.00229	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000531	0.00229	CcSEcCtD
Lisdexamfetamine—Anorexia—Paclitaxel—ovarian cancer	0.000523	0.00226	CcSEcCtD
Lisdexamfetamine—Vomiting—Vinorelbine—ovarian cancer	0.000519	0.00224	CcSEcCtD
Lisdexamfetamine—Rash—Vinorelbine—ovarian cancer	0.000515	0.00222	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vinorelbine—ovarian cancer	0.000514	0.00222	CcSEcCtD
Lisdexamfetamine—Headache—Vinorelbine—ovarian cancer	0.000511	0.0022	CcSEcCtD
Lisdexamfetamine—Palpitations—Docetaxel—ovarian cancer	0.000504	0.00217	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—ovarian cancer	0.000502	0.00217	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—ovarian cancer	0.000499	0.00215	CcSEcCtD
Lisdexamfetamine—Insomnia—Paclitaxel—ovarian cancer	0.000496	0.00214	CcSEcCtD
Lisdexamfetamine—Convulsion—Docetaxel—ovarian cancer	0.000494	0.00213	CcSEcCtD
Lisdexamfetamine—Hypertension—Docetaxel—ovarian cancer	0.000492	0.00212	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Paclitaxel—ovarian cancer	0.000489	0.00211	CcSEcCtD
Lisdexamfetamine—Somnolence—Paclitaxel—ovarian cancer	0.000488	0.0021	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000488	0.0021	CcSEcCtD
Lisdexamfetamine—Nausea—Vinorelbine—ovarian cancer	0.000485	0.00209	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Paclitaxel—ovarian cancer	0.000483	0.00208	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000482	0.00208	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Paclitaxel—ovarian cancer	0.000477	0.00206	CcSEcCtD
Lisdexamfetamine—Dry mouth—Docetaxel—ovarian cancer	0.000475	0.00205	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000474	0.00204	CcSEcCtD
Lisdexamfetamine—Fatigue—Paclitaxel—ovarian cancer	0.000473	0.00204	CcSEcCtD
Lisdexamfetamine—Constipation—Paclitaxel—ovarian cancer	0.000469	0.00202	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000465	0.00201	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000465	0.00201	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—ovarian cancer	0.000465	0.002	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—ovarian cancer	0.000462	0.00199	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Docetaxel—ovarian cancer	0.000456	0.00197	CcSEcCtD
Lisdexamfetamine—Tachycardia—Docetaxel—ovarian cancer	0.000454	0.00196	CcSEcCtD
Lisdexamfetamine—Skin disorder—Docetaxel—ovarian cancer	0.000452	0.00195	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000451	0.00195	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—NSF—ovarian cancer	0.000451	0.0183	CbGpPWpGaD
Lisdexamfetamine—Anorexia—Docetaxel—ovarian cancer	0.000443	0.00191	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—ovarian cancer	0.000442	0.0019	CcSEcCtD
Lisdexamfetamine—Urticaria—Paclitaxel—ovarian cancer	0.000436	0.00188	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Paclitaxel—ovarian cancer	0.000434	0.00187	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000431	0.00186	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—ovarian cancer	0.000426	0.00184	CcSEcCtD
Lisdexamfetamine—Insomnia—Docetaxel—ovarian cancer	0.000421	0.00181	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—ovarian cancer	0.000418	0.0018	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Docetaxel—ovarian cancer	0.000415	0.00179	CcSEcCtD
Lisdexamfetamine—Somnolence—Docetaxel—ovarian cancer	0.000414	0.00178	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—ovarian cancer	0.000413	0.00178	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—ovarian cancer	0.00041	0.00177	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Docetaxel—ovarian cancer	0.00041	0.00177	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—ovarian cancer	0.000409	0.00176	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Docetaxel—ovarian cancer	0.000404	0.00174	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000404	0.00174	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000402	0.00173	CcSEcCtD
Lisdexamfetamine—Fatigue—Docetaxel—ovarian cancer	0.000401	0.00173	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—ovarian cancer	0.000399	0.00172	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000398	0.00172	CcSEcCtD
Lisdexamfetamine—Constipation—Docetaxel—ovarian cancer	0.000398	0.00172	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—ovarian cancer	0.000394	0.0017	CcSEcCtD
Lisdexamfetamine—Asthenia—Paclitaxel—ovarian cancer	0.000394	0.0017	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—ovarian cancer	0.000387	0.00167	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—ovarian cancer	0.000386	0.00167	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—ovarian cancer	0.000384	0.00166	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—ovarian cancer	0.000382	0.00165	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000379	0.00164	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Paclitaxel—ovarian cancer	0.000376	0.00162	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—ovarian cancer	0.000373	0.00161	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—ovarian cancer	0.000369	0.00159	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000368	0.00159	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Docetaxel—ovarian cancer	0.000368	0.00159	CcSEcCtD
Lisdexamfetamine—Dizziness—Paclitaxel—ovarian cancer	0.000363	0.00157	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—ovarian cancer	0.000362	0.00156	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—ovarian cancer	0.000358	0.00154	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—ovarian cancer	0.000356	0.00153	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CCNE1—ovarian cancer	0.000354	0.0144	CbGpPWpGaD
Lisdexamfetamine—Agitation—Epirubicin—ovarian cancer	0.000353	0.00152	CcSEcCtD
Lisdexamfetamine—Vomiting—Paclitaxel—ovarian cancer	0.000349	0.0015	CcSEcCtD
Lisdexamfetamine—Rash—Paclitaxel—ovarian cancer	0.000346	0.00149	CcSEcCtD
Lisdexamfetamine—Dermatitis—Paclitaxel—ovarian cancer	0.000346	0.00149	CcSEcCtD
Lisdexamfetamine—SLC18A2—Neuronal System—NSF—ovarian cancer	0.000346	0.014	CbGpPWpGaD
Lisdexamfetamine—Nervousness—Doxorubicin—ovarian cancer	0.000346	0.00149	CcSEcCtD
Lisdexamfetamine—Headache—Paclitaxel—ovarian cancer	0.000344	0.00148	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Docetaxel—ovarian cancer	0.000343	0.00148	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—ovarian cancer	0.00034	0.00147	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—ovarian cancer	0.000335	0.00145	CcSEcCtD
Lisdexamfetamine—Asthenia—Docetaxel—ovarian cancer	0.000334	0.00144	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—ovarian cancer	0.000333	0.00144	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—ovarian cancer	0.000332	0.00143	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—ovarian cancer	0.000327	0.00141	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—ovarian cancer	0.000326	0.00141	CcSEcCtD
Lisdexamfetamine—Nausea—Paclitaxel—ovarian cancer	0.000326	0.00141	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000325	0.0014	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—ovarian cancer	0.00032	0.00138	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Docetaxel—ovarian cancer	0.000318	0.00137	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—ovarian cancer	0.000314	0.00136	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000314	0.00135	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—ovarian cancer	0.000308	0.00133	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—ovarian cancer	0.000308	0.00133	CcSEcCtD
Lisdexamfetamine—Dizziness—Docetaxel—ovarian cancer	0.000308	0.00133	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—ovarian cancer	0.000307	0.00132	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—ovarian cancer	0.000306	0.0124	CbGpPWpGaD
Lisdexamfetamine—Tachycardia—Epirubicin—ovarian cancer	0.000306	0.00132	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—ovarian cancer	0.000305	0.00131	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000303	0.00131	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—ovarian cancer	0.000302	0.0013	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000301	0.0013	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—ovarian cancer	0.000299	0.00129	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—ovarian cancer	0.000296	0.00128	CcSEcCtD
Lisdexamfetamine—Vomiting—Docetaxel—ovarian cancer	0.000296	0.00128	CcSEcCtD
Lisdexamfetamine—Rash—Docetaxel—ovarian cancer	0.000293	0.00126	CcSEcCtD
Lisdexamfetamine—Dermatitis—Docetaxel—ovarian cancer	0.000293	0.00126	CcSEcCtD
Lisdexamfetamine—Headache—Docetaxel—ovarian cancer	0.000291	0.00126	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.00029	0.00125	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000285	0.00123	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—ovarian cancer	0.000284	0.00122	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—ovarian cancer	0.000283	0.00122	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—ovarian cancer	0.000282	0.00122	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000281	0.00121	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—ovarian cancer	0.00028	0.00121	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—ovarian cancer	0.000279	0.0012	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—ovarian cancer	0.000277	0.00119	CcSEcCtD
Lisdexamfetamine—Nausea—Docetaxel—ovarian cancer	0.000276	0.00119	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—ovarian cancer	0.000276	0.00119	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—ovarian cancer	0.000273	0.00118	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000271	0.00117	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—ovarian cancer	0.000271	0.00117	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—NSF—ovarian cancer	0.000269	0.0109	CbGpPWpGaD
Lisdexamfetamine—Constipation—Epirubicin—ovarian cancer	0.000268	0.00116	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—ovarian cancer	0.000263	0.00113	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Doxorubicin—ovarian cancer	0.000259	0.00112	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—ovarian cancer	0.000258	0.00111	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—ovarian cancer	0.000256	0.0011	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—FASN—ovarian cancer	0.000255	0.0104	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Doxorubicin—ovarian cancer	0.000252	0.00109	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000251	0.00108	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—ovarian cancer	0.00025	0.00108	CcSEcCtD
Lisdexamfetamine—Urticaria—Epirubicin—ovarian cancer	0.000249	0.00108	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—ovarian cancer	0.000248	0.00107	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—ovarian cancer	0.000248	0.00107	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Epirubicin—ovarian cancer	0.000231	0.000997	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—ovarian cancer	0.000231	0.000995	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—ovarian cancer	0.00023	0.00099	CcSEcCtD
Lisdexamfetamine—Asthenia—Epirubicin—ovarian cancer	0.000225	0.000971	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Epirubicin—ovarian cancer	0.000215	0.000926	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000214	0.000922	CcSEcCtD
Lisdexamfetamine—Asthenia—Doxorubicin—ovarian cancer	0.000208	0.000898	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—ovarian cancer	0.000208	0.000895	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—NSF—ovarian cancer	0.000206	0.00836	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Epirubicin—ovarian cancer	0.0002	0.00086	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—ovarian cancer	0.000199	0.000857	CcSEcCtD
Lisdexamfetamine—Rash—Epirubicin—ovarian cancer	0.000198	0.000853	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—ovarian cancer	0.000198	0.000852	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—ovarian cancer	0.000197	0.000848	CcSEcCtD
Lisdexamfetamine—Dizziness—Doxorubicin—ovarian cancer	0.000192	0.000828	CcSEcCtD
Lisdexamfetamine—Nausea—Epirubicin—ovarian cancer	0.000186	0.000804	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—ovarian cancer	0.000185	0.000796	CcSEcCtD
Lisdexamfetamine—Rash—Doxorubicin—ovarian cancer	0.000183	0.000789	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—ovarian cancer	0.000183	0.000789	CcSEcCtD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—ovarian cancer	0.000183	0.00741	CbGpPWpGaD
Lisdexamfetamine—Headache—Doxorubicin—ovarian cancer	0.000182	0.000784	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—ovarian cancer	0.00018	0.0073	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC5A5—ovarian cancer	0.000179	0.00724	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC2A1—ovarian cancer	0.000172	0.007	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—ovarian cancer	0.000172	0.000744	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000168	0.00682	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.000167	0.00679	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.000162	0.00655	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000161	0.00654	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC5A5—ovarian cancer	0.000158	0.00642	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC2A1—ovarian cancer	0.000153	0.0062	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CG—ovarian cancer	0.000138	0.0056	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP2—ovarian cancer	0.00013	0.00527	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000127	0.00517	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CD—ovarian cancer	0.000121	0.00492	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000113	0.00459	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.000113	0.00457	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PIK3CB—ovarian cancer	0.000112	0.00455	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.000109	0.00441	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000108	0.0044	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CXCL8—ovarian cancer	0.000108	0.00438	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—MTOR—ovarian cancer	0.000106	0.00429	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CB—ovarian cancer	0.000106	0.00429	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—ovarian cancer	0.000103	0.00419	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.0001	0.00406	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	9.97e-05	0.00404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—ovarian cancer	9.76e-05	0.00396	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	9.63e-05	0.00391	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ATP7B—ovarian cancer	9.61e-05	0.0039	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.57e-05	0.00348	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	8.5e-05	0.00345	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	8.21e-05	0.00333	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—ovarian cancer	7.89e-05	0.0032	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TUBB3—ovarian cancer	7.59e-05	0.00308	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	6.48e-05	0.00263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—ovarian cancer	6.44e-05	0.00261	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HRAS—ovarian cancer	6.33e-05	0.00257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSD17B6—ovarian cancer	6.24e-05	0.00253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—ovarian cancer	6.23e-05	0.00253	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	6.1e-05	0.00248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—ovarian cancer	6.03e-05	0.00245	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	5.78e-05	0.00235	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.72e-05	0.00232	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—ovarian cancer	5.59e-05	0.00227	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.52e-05	0.00224	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DLC1—ovarian cancer	5.3e-05	0.00215	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—ovarian cancer	5.26e-05	0.00214	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.07e-05	0.00206	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—ovarian cancer	4.9e-05	0.00199	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.89e-05	0.00199	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MAPK1—ovarian cancer	4.68e-05	0.0019	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.36e-05	0.00177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BCL9—ovarian cancer	4.32e-05	0.00175	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.86e-05	0.00157	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—ovarian cancer	3.76e-05	0.00152	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.64e-05	0.00148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DOK1—ovarian cancer	3.42e-05	0.00139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	3.28e-05	0.00133	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP1CC—ovarian cancer	3.21e-05	0.0013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	3.14e-05	0.00128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	3.03e-05	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	2.99e-05	0.00121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	2.99e-05	0.00121	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.92e-05	0.00119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—ovarian cancer	2.9e-05	0.00118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	2.83e-05	0.00115	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MAPK1—ovarian cancer	2.79e-05	0.00113	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	2.6e-05	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC6—ovarian cancer	2.44e-05	0.000988	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPP2R1A—ovarian cancer	2.4e-05	0.000975	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	2.4e-05	0.000974	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—ovarian cancer	2.31e-05	0.000936	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	2.3e-05	0.000932	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—ovarian cancer	2.24e-05	0.000908	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—YAP1—ovarian cancer	2.16e-05	0.000874	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—XIAP—ovarian cancer	2.11e-05	0.000857	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMARCA4—ovarian cancer	2.06e-05	0.000835	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EREG—ovarian cancer	2.01e-05	0.000815	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PGR—ovarian cancer	1.88e-05	0.000763	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—ovarian cancer	1.77e-05	0.000718	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PARP1—ovarian cancer	1.75e-05	0.00071	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6ST—ovarian cancer	1.67e-05	0.000679	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—ovarian cancer	1.61e-05	0.000652	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—ovarian cancer	1.56e-05	0.000632	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP2R1A—ovarian cancer	1.42e-05	0.000576	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—ovarian cancer	1.41e-05	0.000573	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—ovarian cancer	1.36e-05	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—ovarian cancer	1.3e-05	0.000529	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—ovarian cancer	1.25e-05	0.000506	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—ovarian cancer	1.23e-05	0.0005	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—ovarian cancer	1.18e-05	0.00048	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—ovarian cancer	1.13e-05	0.000459	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—ovarian cancer	1.13e-05	0.000457	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—ovarian cancer	1.04e-05	0.000423	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ESR1—ovarian cancer	1.01e-05	0.000408	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6ST—ovarian cancer	9.89e-06	0.000401	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—ovarian cancer	9.5e-06	0.000385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—ovarian cancer	9.5e-06	0.000385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NRAS—ovarian cancer	9.5e-06	0.000385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK3—ovarian cancer	9.1e-06	0.000369	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK1—ovarian cancer	8.66e-06	0.000351	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—ovarian cancer	8.66e-06	0.000351	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—ovarian cancer	8.35e-06	0.000339	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—ovarian cancer	8.27e-06	0.000336	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—ovarian cancer	8.18e-06	0.000332	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	7.51e-06	0.000305	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	7.38e-06	0.000299	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	7.28e-06	0.000295	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	7.28e-06	0.000295	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	7e-06	0.000284	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	6.95e-06	0.000282	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	6.83e-06	0.000277	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	6.76e-06	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	6.7e-06	0.000272	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—ovarian cancer	6.69e-06	0.000271	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	6.65e-06	0.00027	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	6.52e-06	0.000264	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	6.45e-06	0.000262	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	6.33e-06	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	6.29e-06	0.000255	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	6.14e-06	0.000249	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	5.68e-06	0.00023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	5.63e-06	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	5.61e-06	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	5.37e-06	0.000218	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	5.23e-06	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	5.11e-06	0.000207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	5.11e-06	0.000207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	4.83e-06	0.000196	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	4.44e-06	0.00018	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	4.29e-06	0.000174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	4.11e-06	0.000167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	3.93e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	3.63e-06	0.000147	CbGpPWpGaD
